Brought to you by 
Vitae nets $38.6mm via FOPO
01 Jun 2021
Executive Summary
In its first FOPO since going public four months ago, Vitae Pharmaceuticals Inc. (developed the Contour structure-based drug discovery platform) netted $38.6mm through the follow-on public offering of 3.45mm common shares (including the overallotment) at $11.90 per share. Funds will help progress development of its candidates including Phase II VTP43742 for Type II diabetes, and preclinical VTP38543 and VTP38443 for atopic dermatitis and acute coronary syndrome, respectively.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vitae nets $38.6mm via FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice